Companies / Health Care / Biotechnology
Regeneron Pharmaceuticals stock buybacks
REGN$3.3Bbought back in the 12 months to Jun 30, 2026
Regeneron Pharmaceuticals bought back $3.3B of its stock in the last twelve months, $2.3B more than it paid out in stock compensation. Its share count is down 2.4% from a year earlier.
Show as table
| Period | Value |
|---|---|
| Q3 '20 | $92.1M |
| Q4 '20 | $381.1M |
| Q1 '21 | $306.9M |
| Q2 '21 | $305.2M |
| Q3 '21 | $166.4M |
| Q4 '21 | $866.9M |
| Q1 '22 | $358.1M |
| Q2 '22 | $359M |
| Q3 '22 | $934.6M |
| Q4 '22 | $431.1M |
| Q1 '23 | $710.7M |
| Q2 '23 | $688.8M |
| Q3 '23 | $546.5M |
| Q4 '23 | $289M |
| Q1 '24 | $291.3M |
| Q2 '24 | $603.9M |
| Q3 '24 | $735.1M |
| Q4 '24 | $973M |
| Q1 '25 | $1.0B |
| Q2 '25 | $1.1B |
| Q3 '25 | $664M |
| Q4 '25 | $671.7M |
| Q1 '26 | $794.3M |
| Q2 '26 | $1.2B |
Show as table
| Period | Value |
|---|---|
| Q3 '20 | 113.9M |
| Q4 '20 | 113.5M |
| Q1 '21 | 110.5M |
| Q2 '21 | 110.8M |
| Q3 '21 | 113.9M |
| Q4 '21 | 113.6M |
| Q1 '22 | 113.1M |
| Q2 '22 | 114.0M |
| Q3 '22 | 112.8M |
| Q4 '22 | 114.1M |
| Q1 '23 | 114.0M |
| Q2 '23 | 113.9M |
| Q3 '23 | 113.4M |
| Q4 '23 | 113.5M |
| Q1 '24 | 115.1M |
| Q2 '24 | 115.4M |
| Q3 '24 | 116.2M |
| Q4 '24 | 113.7M |
| Q1 '25 | 111.2M |
| Q2 '25 | 108.6M |
| Q3 '25 | 107.2M |
| Q4 '25 | 107.4M |
| Q1 '26 | 107.7M |
| Q2 '26 | 106.0M |
$1.2Blast quarter (Q2 2026)
$2.3Bnet of stock compensation ($987M)
−2.4%diluted shares, 1 year
−5.6%diluted shares, 5 years
$379Mdividends, 12 months
88%of free cash flow ($3.8B) spent on buybacks
$756Mraised by issuing stock, 12 months
$2.5Bleft under its authorization as of Jun 30, 2026
By fiscal year
Questions
- Does Regeneron Pharmaceuticals buy back its stock?
- Regeneron Pharmaceuticals bought back $3.3B of its stock in the last twelve months, $2.3B more than it paid out in stock compensation. Its share count is down 2.4% from a year earlier.
- How much did Regeneron Pharmaceuticals spend on buybacks in fiscal 2025?
- $3.4B, according to its 10-K for the fiscal year ending Dec 31, 2025.
- Is Regeneron Pharmaceuticals's share count going down?
- Its diluted share count changed −5.6% over five fiscal years and −2.4% over the last year.
- Does Regeneron Pharmaceuticals have a buyback authorization?
- Its filings show $2.5B remaining under its repurchase authorization as of Jun 30, 2026.
Latest filing used: 10-Q for the period ending Jun 30, 2026, filed Jul 30, 2026 · open on SEC.gov